Discover Oncology (Mar 2023)

Comparison of two high dose rate intracavitary brachytherapy regimens in treatment of cervical cancer: a preliminary report

  • Abhishek Krishna,
  • AG Hasib,
  • Donald Fernandes,
  • M. S. Athiyamaan,
  • Sandesh Rao,
  • Sharaschandra Shankar,
  • Mohsina Ali,
  • Hepsiba Priyadarshini,
  • Maria Sophia,
  • CH Shridhar,
  • Seby George,
  • Amrutha Babu,
  • Sourjya Banerjee,
  • Johan Sunny,
  • Challapalli Srinivas,
  • Dilson Lobo

DOI
https://doi.org/10.1007/s12672-023-00646-x
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 9

Abstract

Read online

Abstract Background To assess and compare the local control and toxicities between HDR Intracavitary Brachytherapy with 7.5 Gy and 9 Gy per fraction after EBRT in treatment of carcinoma cervix. Methodology A total of 180 patients were randomly assigned to 2 arms. Arm A received HDR intracavitary brachytherapy with a dose of 7.5 Gy per fraction, 1 fraction per week for 3 fractions and Arm B received 9 Gy per fraction, 1 fraction per week for 2 fractions. Patients were evaluated on follow up for assessment of local control and toxicities. Results The median follow up was 12 months (6–18 months). In arm A 89% of the patient had complete response and 11% had recurrence or metastasis. In arm B 93% of the patient had complete response and 7% had recurrence or metastasis. Grade 2/3 diarrhoea was seen in 4.4% of patients in Arm A and in 7.7% in Arm B. Grade 2/3 proctitis was seen in 3.3% of patients in 7.5 Gy arm and in 6.6% in 9 Gy arm. One patient in each arm had grade 1 haematuria. The overall duration of treatment was significant lower in Arm B compared to Arm A (59 days vs 68 days, p = 0.01). Conclusion The result of this clinical study shows that Intracavitary brachytherapy with a dose of 9 Gy per fraction is non inferior to other schedules in term of local control and does not result in increased toxicity.

Keywords